The proteomics technology provider, backed by Nan Fung, iCarbonX, Novartis, Otsuka and Quest Diagnostics, has now secured $485m in total.
SomaLogic, a US-based proteomics therapy developer backed by several corporate investors, raised $121m yesterday in a series A round led by life sciences investment firm Casdin Capital.
Farallon Capital Management, Foresite Capital, Blue Water Life Science Advisors, Madryn Asset Management, Fiscus Ventures, Reimagined Ventures, Monashee Investment Management, Mossrock Capital, Soleus Capital and funds and accounts advised by T. Rowe Price also took part in the round.
Founded in 2000, SomaLogic has developed technology that can track precise changes in an…
